Compare Abeona Therapeutics Inc (ABEO) vs Aspen Aerogels Inc (ASPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Aspen Aerogels Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Aspen Aerogels Inc trades at $5.14 (market cap $425.99M). The key difference: Abeona Therapeutics Inc and Aspen Aerogels Inc are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ASPN | |
|---|---|---|
Market Cap | $373.32M | $425.99M |
Sector | Health | Technology |
52-Week High | $7.23 | $8.82 |
52-Week Low | $4.17 | $2.57 |
Enterprise Value | $228.22M | $380.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ASPN trades at $5.47, down 1.97% today, with a bearish technical signal despite bullish moving averages. The company reported a Q1 2026 net loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility after an incident. Cash flow improved in 2026 projections, with net cash flow narrowing to -$17 million from -$63 million in 2025.
Outlook remains challenging with persistent losses and negative margins, but analyst sentiment is strongly bullish (83% buy ratings). Key risks include execution on facility restarts, EV demand volatility, and cash burn. The stock's investment case hinges on operational turnaround and revenue growth acceleration amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →
